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Abstract
Introduction: Glioblastoma multiforme (GBM) is one of the deadliest forms of
brain cancer, and affects more than 18,000 new cases each year in the United
States alone. The current standard of treatment for GBM includes surgical
removal of the tumor, along with radiation and chemotherapy. Despite these
treatments, recurrence of GBM is extremely common, and once it recurs, the life
expectancy is measured in weeks or months. One of the reasons for the deadly
nature of the recurrent GBM is thought to be selection for therapy-resistant tumor
cells. In this project, we sought to characterize the molecular changes in recurrent
GBM specimens compared to primary GBM specimens from the same subjects.
Methods: Whole-genome DNA microarrays were used to identify genes changed
in mRNA expression in seven recurrent GBM samples compared to seven
primary GBM samples from the same subjects. Real-time quantitative RT-PCR
was used in an attempt to validate changes seen by microarray for 18 genes of
interest chosen from the microarray screen.
Results: The microarray experiments identified several dozen mRNA transcripts
with evidence of significant differences in expression. From these genes, we
chose 18 for PCR validation. Overall, the PCR experiments validated the
microarray findings quite well. There was a very high correlation for the
magnitude of expression changes seen for the 18 genes (Pearson’s R = 0.852, P <
0.001). Individually, 13 of the 18 genes showed statistically significant changes
by PCR in the recurrent versus primary tumor pairs. Of the 5 genes that did not

validate at the P<0.05 level, 4 showed trends in the direction predicted by the
microarray, while 1 gene did not.

Conclusion: Real time PCR has proven useful for validating changes in recurrent
GBMs that could have important clinical applications.
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Abbreviations:
ANTXR1 anthrax toxin receptor 1
CCND2

cyclin D2

cDNA

complementary DNA

CLDN2

claudin 2

Cp

cycles to pass threshold

CSPG4

chondroitin sulfate proteoglycan 4

CSPG5

chondroitin sulfate proteoglycan 5 (neuroglycan C)

EDIL3

EGF-like repeats and discoidin I-like domains 3

EGFR

epidermal growth factor receptor (erythroblastic leukemia viral (v-erbb) oncogene homolog, avian)

ENPP2

ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin)

GALNT6 UDP-N-acetyl-alpha-D-galactosamine:polypeptide Nacetylgalactosaminyltransferase 6 (GalNAc-T6)
GBM

glioblastoma multiforme

NCAN

neurocan

NPTX2

neuronal pentraxin II

PCR

polymerase chain reaction

iii

PTPRZ1

protein tyrosine phosphatase, receptor-type, Z polypeptide 1

qPCR

quantitative real-time PCR

RNA

ribonucleic acid

RT

reverse transcription

SNCA

synuclein, alpha (non A4 component of amyloid precursor)

SNCAIP synuclein, alpha interacting protein (synphilin)
SNP

single nucleotide polymorphism

ST18

suppression of tumorigenicity 18 (breast carcinoma) (zinc finger

protein)
STK17A serine/threonine kinase 17a
SYN2

synapsin II

TPPP

tubulin polymerization promoting protein
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Introduction:
Tumors of the brain are one of the toughest types of cancers to study and
treat. “Over 34,000 (1.5%) of the
1.1 million cancers diagnosed
annually in the United States are
found to involve the brain.
Approximately 17,000 of these are
primary intracranial origin, with the
remainder resulting from
intracranial metastasis,” (Grossman
and Loftus, 1999). “Approximately

Figure 1: Coronal section anterior view revealing a GBM. Extracted
from Grossman and Loftus, 1999.

50% of all tumors occurring within
the intracranial cavity fall under the
heading ‘glioma.’ (Grossman and
Loftus, 1999). Gliomas are defined as
“a hetereogenous collection of
neoplasms unified by the fact that they
arise from glial tissues,” (Grossman and
Loftus, 1999). Glioblastoma Multiforme
(GBM) is the deadliest form of brain
cancer. GBM is a type of astrocytic
primary intracranial tumor that

Figure 2: Giant Cell GBM showing enlarged neoplastic glial cells.
Extracted from Grossman and Loftus, 1999.
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accounts for 15-23% of cases. 35% of these cases are gliomas (Grossman and
Loftus, 1999) (see Figure 1). As stated before, gliomas are tumors of glial origin
(see Figure 2). Over 80% of gliomas are derived from astrocytic components of
the glia. These tumors, termed astrocytomas, are the most common form of
primary intracranial malignancy,” (Grossman and Loftus, 1999).Glial cells are
non neuronal cells in the brain that are responsible for balance, destruction of
pathogens, removal of dead neurons, and provision of insulation and oxygen for
other neurons. The World Health Organization (WHO) characterizes GBM as a
grade IV astrocytic tumor (Louis et. al). It is the most common and aggressive
brain tumor.
These intracranial tumors are the least differentiated and the most
aggressive form of astrocytomas (Grossman and Loftus, 1999). Research has
shown that the “intratumoral signal heterogeneity is apparent in the vast majority
of cases and is thought to represent cystic, hemorrhage, and variability in cellular
density,” (Grossman and Loftus, 1999). Furthermore, GBMs are characterized by
“the presence of an irregular rim of
high signal intensity, which
probably represents tumor mantle,
where hemosiderin deposits,
breakdown of the blood brain
barrier (BBB), and a high nuclear to
cytoplasmic ratio are present,”
(Grossman and Loftus, 1999).
Figure 3: Necrosis due to GBM Extracted from Grossman and Loftus,
1999.
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These rapidly dividing cells in the brain derived from glial cells characterized by
a centrally located necrotic area, which is also extremely hypoxic (see Figure 3).
The hypoxic area develops as the tumor outgrows its blood supply and spreads
throughout the neighboring cells. The tumor tissue is hypercellular and if
examined under a microscope, it would show high cellular density and mitotic
activity of the rapidly dividing cells (Grossman and Loftus, 1999). The rapid
division gives the tumor the ability to diffuse and infiltrate nearby areas resulting
in inferior survival and short time to recurrence (Showalter et al., 2007). The
necrotic center and the endothelial proliferation are characteristics commonly
used to differentiate
this tumor from
another grade of
astrocytoma
(Grossman and
Loftus, 1999).
Figure 4: Survival rate of patients with GBMs is poor. Extracted from Ohgaki
and Kleihues, 2005).

Research has also
indicated that

“necrosis is associated with significantly worse prognosis in anaplastic gliomas
with both oligdendroglial and astrocytic components,” (Louis et al., 2007). The
overall median survival rate is lower in patients with a necrotic center than the
patients without (Louis et al., 2007).
Despite it being the most common type of brain cancer, there is no definite
cure for GBM and research is ongoing but limited by the low life expectancy of
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the patients diagnosed with GBM (see Figure 4). Treatment of the tumor involves
a combination of surgery, radiation, and chemotherapy. The patients are usually
given more than one of these treatments at a time. Average survival after the
primary GBM treatment is about 12 months (Loftus and Grossman, 1999). “The
most common cause of mortality among patients with glioblastoma, regardless of
age, is recurrence at the primary tumor site,” (Loftus and Grossman, 1999). The
average survival after diagnosis of recurrent tumor is only couple months
maximum. Researchers and physicians currently recommend aggressive and
postoperative radiation because improved survival rates have been correlated with
aggressive resection (Grossman and Loftus, 1999). It is important to recognize,
though, that combinations
of treatment are highly
dependent on the health
status of the person. With
age, the treatment available
for the patient is minimal.
Younger patients (usually
less than 40) are able to
withstand aggressive
treatment but older patients are
not (Ohgaki and Kleihues, 2005)

Figure 5: Age at diagnosis plays an important role in the life
expectancy o f a GBMpatient. Table shows that the older the
patient, the lower the life expectancy after diagnosis. Extracted
from Ohgaki and Kleihues, 2005).

(see Figure 5). Furthermore, the effectiveness of chemotherapy treatments in
conjunction to radiation and total resection are reduced due to the heterogeneity of
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the GBM tumor cells. “As a result of this heterogeneity, each subpopulation of
cells within a neoplasm may manifest variability in its sensitivity to treatments
such as chemotherapy. Additionally, glioblastomas may be heterogeneous with
respect to their physical structure, often containing differing microenvironments
within the same tumor mass,” (Loftus and Grossman, 1999). Marginally viable
but extremely resistant tumor cells can be spotted in the necrotic region of the
GBM tumor which could have gotten past the drug penetration presented by
radiation treatments or any other type of intervention, thus, lengthening the cell
cycle, while using the hypoxia as a cover (Loftus and Grossman, 1999). Current
research focuses on what makes the primary vs. recurrent tumor so heterogeneous
even though they have essentially originated from the same group of cells.
There are two types of GBMs: Primary and Recurrent. Primary GBMs are
tumors that stay in the region of the origin of the malignant mass (see Figure 6a
& 7). Primary tumors are usually treated with a combination of surgery and
radiation. Adjuvant chemotherapy treatment varies on the patient’s profile and
health status.

Figure 6a: Primary GBM tumor with a clear site of origin.
Extracted from Loftus and Grossman, 1999).

Figure 6b: Recurrent GBM tumor spreading out to
different parts of the brain. Original site of tumor can
still be seen.
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As stated before, aggressive therapy of the primary tumor increases life
expectancy to about 8-12 months. On the other hand, recurrent GBMs are tumors
that have originated in the brain but then have
metastasized to different parts of the brain and
possibly other organs as well (see Figure 6b &
8). This type of tumor is even harder to treat
than the primary tumor because of its
pathogenic characteristics. These tumors cells
were able to resist primary aggressive therapy
and have the ability to proliferate and invade at
Figure 7:Primary GBM with necrotic center.

a higher rate than the primary tumor. Due to this

reason, the life expectancy after the treatment or even diagnosis of the recurrent
tumor is only about 2 months (at the most). There is a clear heterogeneous
difference between the primary and the
recurrent tumors, but there is not enough
research to pinpoint the difference on a
molecular level. Research indicates that there
are certain genetic markers that differ from
one grade to next grade of GBM. Certain
genes end up being over or under expressed as
needed for the cancerous cells to proliferate
and spread throughout the brain (Ohgaki and
Kleihues, 2005).

Figure 8: Metastatic primary tumor showing
multiple foci. Extracted from Loftus and Grossman,
1999).
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Presentation of the tumor and patient profile is very different for GBMs
compared to any other type of tumor. Presentation of the tumor in adults shows
with severe, unbearable headaches due to the edema and pushing of the tumor
against the cranial chamber, seizures, bleeding, decomposition, reduction of the
brain’s ability to handle stressful situations or stress in general, weak focal vision.
In adults, the tumor is mostly supra
supra-tentorial.
tentorial. The tentorium separates the cerebral
hemisphere from the brain stem and cerebellum and supra means above.
Therefore, in adults the tumor is mostly in the cerebral hemisphere. Moreover, the
tumor is mostly large in adults and presents in grade
2, 3, 4 stage. On the other hand, in children, this
tumor is usually grade 1and infra-tentorial tumor with
cerebellar signs, nausea, and vomiting (Loftus and
Grossman, 1999).
When a patient is presented with a case of
GBM, if he/she is in decent health, then the tumor is
resected. On average, MOST of the time there is
recurrence (see
see Figure 99). The second time, if the
person is healthy enough, the physician tries to resect

Figure 9: Reccurent GBM taking over the brain.
Notice that it is impossible to determine where
the brain starts and the tumor ends.

that tumor as well. In either case, the goal is to buy time for the patient. In
Table 1:: Univariate analysis for the Effect of Genetic Alterations on Survi
Survival and
Mean Age of GBM Patients. Extracted from Ohgaki an
and Kleihues, 2005).

primary tumors, the
person gets about a
year, in recurrent
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treatment, the person gets a few weeks. There is a lot of debate over the palliative
treatment because if there is such a small time frame for survival, then why go
through the aggressive treatment once or even twice? A GBM case is presented
differently than any other form of cancer. Usually, a healthy patient is rushed into
the hospital due to severe headache or any other symptom, diagnosed with brain
tumor, taken to surgery usually at that visit, and then told that they only have
about one year left. The time bought from the surgery is very much appreciated
by the patients and it is also helpful for research purposes.
Survival rate of GBM patients is 0.1%; therefore, any type of molecular
change that can be determined could be helpful in the understanding of the
heterogeneity of the different grades of GBM tumors. Previous research has
shown genetic alternation association with GBM tumors. “… LOH 10q was the
most frequent genetic alteration (69%), followed by EGFR amplification (34%),
TP53 mutations (31%), p16INK4a deletion
(31%), and PTEN mutations (24%),”(Ohgaki
and Kleihues, 2005). Although, “studies on
genetic alterations and how they influence
response to therapy and survival are usually
based on small number of patients, often
contradictory and difficult to validate. In
recent years, it has been established that
primary glioblastomas and secondary
glioblastomas derived from low-grade or

Figure 10: Extracted from Ohgaki and Kleihues,
2005. The image shows the age difference of
primary and secondary GBM incidence (top). The
image also describes specific gene changes
occurance correlating age as a factor during
incidence.
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anaplastic gliomas develop though different genetic pathways,” (Ohgaki and
Kleihues, 2005) (see Figure 10 & Table 1). The variation differs on many levels,
including the age of the patient presenting the tumor. Nevertheless, poor
prognosis cannot be defined by genetic alteration especially in older patients.
Studies have shown that, “EGFR amplification, TP53 mutations, p16INK4a
homozygous deletion, and PTEN mutations are considered key genetic events in
the evolution of glioblastomas, but the presence or absence of any of these
changes does not affect survival,” (Ohgaki and Kleihues, 2005)(see Figure 11 &
12). “Although there may be as yet unidentified transformation-associated genes
that are more frequently altered in glioblastomas of older patients and may affect
the susceptibility to therapy, it is also possible that the sum of all changes, i.e. the
level of genetic instability, is more relevant,” (Ohgaki and Kleihues, 2005). Other
molecular research has indicated that hypermethylation of the MGMT promoter
region could be associated with long term survival (long term GBM patients are
patients who survive more than 36 months) (Krex et al., 2007). The purpose of
this research project focuses on the molecular differences of the primary vs.
recurrent tumors. Why does a full resection for the recurrent tumors less effective
in terms of life expectancy than primary tumor resection?

Figure 11: Gene expressional changes according to age of the patient at the
time of diagnosis. Extracted from Ohgaki and Kleihues, 2005).
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Figure 12: Known gene expressional changes according to grade of astrocytoma. Extracted from Ohgaki and
Kleihues, 2005

Since both primary and recurrent tumors are essentially from the same group of
cells, the research work focuses on looking at molecular changes in the evolution
of cells, DNA copy number changes, and mRNA expression changes. Copy
number changes are a marker of many diseases including cancer. Combining the
genotype and copy number analyses gives greater insight into the underlying
genetic alterations in cancer cells with identification of complex events including
loss and reduplication of loci. This paper specifically looks at cancer related gene
expression changes that showed consistent change in the microarray analysis in
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the recurrent vs. primary tumors of DNA tissue from seven patients with both
primary and recurrent GBMs at Upstate Medical University. A total of 18
candidate genes (many with known roles in cancer proliferation) were selected for
the study from the microarray results for validation: ANTXR1, CCND2, CLDN2,
CSPG3, CSPG4, CSPG5, EDIL3, EGFR, ENPP2, GALNT6, NPTX2, PTPRZ1,
SNCA, SNCAIP, ST18, STK17A, SYN2, and TPPP.
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Methods:
The Upstate Medical University tumor bank has tissues of seven patients
with primary and recurrent GBMs. Three different approaches were used to
determine the molecular changes. All three approaches were initiated with
microarray GeneChip analysis method. Microarray GeneChip analysis uses
probes and targets for different applications such as mutations and differences in
expression on a chromosomal level (see Figure 13). Screening shows markers
that are consistently changing, either increasing or decreasing. The assay
mathematically averages out the noise and finds strong, consistent change. A
downside of this method is that gene expression varies from person to person
even in normal individuals. Therefore, the findings of the microarray analysis
need to be validated to make sure that the expressional changes are due to the
cancer and not just because normal biological genetic variation. As a result, all

Figure 13: Microarray (GeneChip) analysis method
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three approaches were validated with real time quantitative RT-PCR (Real Time
qPCR). Real Time qPCR provides highly sensitive quantitative gene transcription
measurements by amplifying and quantifying DNA simultaneously. Just like
regular polymerase chain reactions, the DNA is denatured, annealed, and
extended in Real Time qPCR method. Moreover, Real Time qPCR involves
attachment of a SYBR green dye to generate signal values. SYBR green dye
specifically binds to double-stranded DNA (dsDNA), but emits no signal when
unbound (in the presence of single stranded DNA). The increase in SYBR green
fluorescence is measured once during each PCR cycle, and the numbers of cycles
it takes for this signal to surpass background is determined (as the delta Cp value).
The real time qPCR studies that were performed were part of the
validation for a multilevel analysis of recurrent GBMs that involved three
complementary approaches. These three types of approaches are characterized on
a convergent flow chart below. RNA expressional changes, DNA copy number
changes, and the promoter methylation changes were focused upon in order to see
which genes play an essential role that could help explain the recurrent vs.
primary tumor changes and ultimately help identify new treatments for GBM (see
Figure 14).
Once the reactions were run for the three approaches, we asked two
pertinent questions: a) Are there any common genes implicated from the
approach? and b) Are these genes implicated in cancer?
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Figure 14: 3-way
way GBM research method for this study

Microarray Methods
Genomic DNA and RNA were purified using standard protocols (Qiagen
RNeasy kit for RNA and the Epicentre DNA purification kit for DNA). The yield,
purity, and integrity of RNA and DNA were confirmed by UV spectrophotometry
and the Agilent Bioanalyzer NanoChip. Changes in RNA expression were
determined
etermined using the Affymetrix U133 plus 2.0 Gene Chip
hip which assays for
hybridization for over 47,000 fragments representing over 38,000 known genes.
A single microarray (Human Genome Xba SNP Array) containing probes for
~58,000 single
ingle nucleotide polymorphism
polymorphisms (SNPs) was also run on the
th DNA from
each tumor sample to probe for changes in DNA copy number, and chromosomal
rearrangements. Lastly, bbecause previous studies
udies have shown that methylation of
DNA at CpG islands in the promoter sites of certain genes correlates with
sensitivity of glioma
lioma cells to chemotherapeutics (including temozolamide,
Everhard 2006),, we also mapped changes in genome-wide
wide promoter methylation
status using a novel assay developed in the SUNY Microarray Core Facility that
is analyzed with the Human Promoter 1.0 Arra
Array (Affymetrix).

15

Real Time RT-PCR Methods
Quantitative real time RT-PCR (qRT-PCR) was performed to validate the
changes seen by microarray screens. Briefly, 500ng of total RNA (in 12 µL PCR
grade water) from each RNA preparation was used in an integrated reverse
transcription (RT) first and second strand cDNA synthesis procedure that
incorporates removal of genomic DNA contamination (QiantiTect, Qiagen,
Valencia, CA). The RT reaction was terminated by heating to 95oC for 3 min, and
diluted to a volume of 100µL for use in qRT-PCR. For quantification of transcript
differences, 1.0 µL of the RT reaction from each of the samples was evaluated in
duplicate PCR reactions for each gene of interest on 384-well plates in a Roche
LightCycler 480 instrument (Roche, Indianapolis, IN).
Each qRT-PCR reaction was performed in duplicate using the Roche
SYBR Green Master Mix, in 10 µL volumes as follows: Activation at 95oC for 5
min, followed by 40 cycles of 95oC for 10 sec, 58oC for 15 sec, and 72oC for 15
sec. Amplification in the absence of cDNA template was used to verify the
absence of signal that would have occurred due to primer dimerization and
extension or DNA contamination and end point melt-curve analysis was used to
confirm the presence of single amplicons in each reaction well.
Analyses of the data from the qRT–PCR studies was performed by first
determining the number of PCR cycles that it took for each reaction to pass the
detection threshold (Cp). Then, to control for differences in starting material,
these values were normalized for each gene from a specific sample by subtracting
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the Cp value of 18S rRNA to generate a ∆Cp value. Statistical significance of the
PCR based differences in expression was determined using a 1-tailed pairwise
Student’s T test. Pairwise relative differences in expression between the recurrent
and primary tumors from the same subject were then determined by subtracting
the ∆Cp value of each gene for the recurrent tumor from the ∆Cp value of the
primary tumor. These differences were termed ∆∆Cp values, and represent the
Log2 difference in expression in recurrent versus primary GBMs. For interpretive
purposes, the Log2 differences can be converted to fold changes using the
formula Fold Change = 2∆∆Cp. In addition to examining the data for evidence of
validating the overall change in expression seen by microarray, we also calculated
the overall correlation in the pairwise differences observed between the recurrent
and primary tumor using a Pearson’s R. All of these values are displayed in the
results that follow. qPCR validation of the genes CLDN2, EDIL3, ENPP2,
NPTX2, PTPRZ1, and STK17A was performed by Dr. Peter Kim. Validations of
the remaining 12 genes were the focus of my research work: ANTXR1, CCND2,
CSPG3, CSPG4, CSPG5, EGFR, GALNT6, SNCA, SNCAIP, ST18, SYN2, and
TPPP.
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Results:
The results of this paper focus on the microarray expression analysis and
their validation using real time qPCR. On the microarray screen, some of the
genes are repeated because there was more than one probe for that particular gene.
T-test results show that most of the genes with expressional differences are
statistically significant. The values that are not are the genes with more than one
probe. Majority of the probes for that specific gene are still statistically
significant. Expressional changes were averaged according to primary minus
recurrent tumors from each of the seven patients on a log 2 scale. A negative
value in the average log 2 column indicated a decrease in expression while a
positive value indicates an increase in gene expression.
Among the initial genes that were validated by Dr. Peter Kim, PTPRZ1
and STK17A showed a decrease in expression while CLDN2, EDIL3, ENPP2,
NPTX2, and SYN2 and showed an increase in expression in the recurrent tumor
vs. primary tumor (see Table 2). Round 2 candidate genes ANTXR1, CCND2,
CSPG3, CSPG4, CSPG5, EGFR, and SNCAIP showed a decrease in expression
whereas GALNT6, SNCA, ST18, SYN2, and TPPP showed an increase in
expression in the recurrent tumor vs. primary tumor (see Table 3).
Overall, there was a high correlation for the magnitude of expression
changes seen for the 18 genes by both approaches (Pearson’s R = 0.852; P <
0.001; see Figure 15). Individually, 13 of the 18 genes showed statistically
significant changes by PCR in the recurrent versus primary tumor pairs. Of the 5
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genes that did not validate at the P<0.05 level, 4 showed trends in the direction
predicted by the microarray, while 1 gene did not.

Table 2: Preliminary (round 1) microarray screen expressional changes and qPCR expressional changes. qPCR t – test
analysis indicates whether the expressional changes from microarray screen were validated.

Preliminary Validation (Fall 2007, performed by Dr. P. Kim)
Pairwise Pairwise
Pairwise Log2 Differences by Microarray Screen
Gene
T Test P Log2 Diff Pair 1
Pair 2
Pair 3
Pair 4
Pair 5
Pair 6
Pair 7
Claudin
0.000005
0.18
0.06
1.10
0.77
0.49
-0.64
0.12
-0.65
ENPP2
0.032863
1.99
0.37
0.00
1.44
0.49
5.88
3.47
2.25
EDIL3
0.054454
1.61
0.66
-0.05
1.17
0.76
4.45
2.77
1.50
NPTX2
0.076730
1.51
0.03
1.02
0.67
0.90
4.58
1.62
1.75
PTPRZ1
0.009154
-1.81
-2.06
-0.82
-4.80
-2.36
-1.40
-0.61
-0.62
STK17A
0.007560
-1.57
-2.41
-2.17
-2.89
-1.15
-1.11
-1.08
-0.21

Gene
Claudin
ENPP2
EDIL3
NPTX2
PTPRZ1
STK17A

T Test P Log2 Diff
0.005773
2.61
0.005117
2.11
0.005230
2.70
0.005251
2.70
0.008861
-1.88
0.021679
-1.03

Pair 1
1.63
1.85
1.03
-0.25
-1.07
-0.41

Pairwise Log2 Differences by PCR
Pair 2
Pair 3
Pair 4
Pair 5
Pair 6
1.33
2.76
2.05
6.37
3.60
0.72
2.50
1.33
4.43
3.62
1.01
2.98
1.79
6.64
3.34
2.97
3.61
2.91
5.98
2.54
-0.15
-4.79
-1.86
-2.40
-0.61
-0.88
-2.08
0.97
-1.67
-1.18

Pair 7
0.55
0.30
2.13
1.15
-2.30
-1.98
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Table 3: Round 2 microarray screen expressional changes and qPCR expressional changes. qPCR t – test analysis indicates
whether the expressional changes from microarray screen were validated.

Round 2 Validation
Gene
ANTXR1
CCND2
CSPG3
CSPG4
CSPG5
EGFR
GALNT6
SNCA
SNCAIP
ST18
SYN2
TPPP

Gene
ANTXR1
CCND2
CSPG3
CSPG4
CSPG5
EGFR
GALNT6
SNCA
SNCAIP
ST18
SYN2
TPPP

T Test P Log2 Diff
0.003806
-1.31
0.022083
-1.01
0.036635
-1.44
0.002523
-1.53
0.001982
-1.17
0.037536
-0.86
0.010349
1.69
0.001518
1.17
0.104891
-1.01
0.004882
1.67
0.000004
0.41
0.018529
1.56

T Test P Log2 Diff
0.063626
-1.30
0.021110
-1.97
0.029636
-2.05
0.020126
-2.32
0.018768
-2.15
0.122273
-0.98
0.041500
0.98
0.228274
0.47
0.032785
-3.27
0.237864
0.35
0.468723
-0.03
0.033173
2.04

Pair 1
-2.00
-1.91
-2.00
-3.10
-1.87
-3.53
2.82
1.47
-1.56
0.26
0.63
0.04

Pair 1
0.11
-0.41
0.68
-0.85
-0.07
-4.50
3.54
1.76
-0.84
1.13
0.10
-2.23

Pairwise Log2 Differences by Microarray Screen
Pair 2
Pair 3
Pair 4
Pair 5
Pair 6
Pair 7
-1.70
-2.28
-2.41
-0.54
-0.40
0.18
-0.64
-2.15
-0.89
-0.50
-0.80
-0.19
-2.05
-2.12
-2.33
-1.24
0.04
-0.37
-1.91
-2.34
-0.69
-0.46
-2.61
0.40
-0.62
-2.82
-0.78
-0.81
-1.31
0.00
0.68
-0.63
-0.47
-1.22
-1.01
0.15
1.42
1.24
3.14
2.17
1.72
-0.66
0.55
2.74
0.02
2.25
1.53
-0.35
-0.47
-2.94
-0.53
-0.48
-0.58
-0.47
0.92
2.25
0.37
4.36
2.60
0.91
0.92
0.91
0.26
-0.22
0.51
-0.11
0.42
1.46
0.34
4.19
2.06
2.41

Pairwise Log2 Differences by PCR
Pair 2
Pair 3
Pair 4
Pair 5
Pair 6
-1.02
0.22
-1.05
-5.32
-2.05
-0.20
-3.43
-0.64
-5.80
-2.03
-0.87
-2.11
-3.79
-6.35
-0.98
-1.42
-1.79
-0.74
-6.94
-4.00
-1.30
-3.07
-1.62
-6.25
-2.67
-1.87
-0.24
0.02
-0.90
-1.45
0.93
0.88
1.04
0.79
-0.03
-0.45
-1.55
1.01
0.14
-0.61
-2.17
-2.16
-10.76
-5.79
-2.02
0.12
1.05
1.49
0.97
-0.38
-0.37
0.60
1.84
-0.20
-0.81
1.07
5.23
0.90
2.78
2.71

Pair 7
-0.01
-1.29
-0.93
-0.51
-0.08
2.08
-0.31
2.98
0.81
-1.95
-1.39
3.80
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Log2 Changes of 18 Selected Genes
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Figure 15: Comparison of changes seen in recurrent versus primary GBM for 18 genes in initial microarray
screen, and real time qPCR. Overall, there was a very high correlation in the difference seen for the two
techniques (Pearson’s R = 0.852, P<0.001).
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Conclusion:
The overall high correlation between the microarray expression analysis
and the qPCR validation results indicates that Real time PCR has proven useful
for validating changes in recurrent GBMs that could have important clinical
applications. Of the round 2 gene validation, 7 out of 12 genes were statistically
significant for expression change. The gene functions are presented in table 4.
The biology of these seven genes can be related to tumor functions.
CCND2 is a cell cycle regulator (Lossos 2004). The average expression of
CCND2 is decreased in the recurrent tumor compared to the primary tumor, thus,
indicating that the high proliferation rate of the recurrent tumor may be the result
of improper function of cell cycle regulator.
CSPG3 (also known as NCAN), CSPG4, and CSPG5 belong to the same
family of genes. They are known to be responsible for the regulation of the
extracellular matrix (Gladson 1999 & Zhang 2003). Real time validation showed
that the average expressions in all three genes are decreased in the recurrent
tumor. This shows that since the matrix is not regulated, the tumor cells can easily
spread to the neighboring cells because there is not traffic in the extracellular
matrix to slow down the proliferation of the tumor cells.
GALNT6 is known to be expressed in low levels in the brain. It is
associated with fibronectin glycosylation kinetics. Furthermore, members of this
family are responsible for the transfer of N-acetylgalactoamine to serine and
threonine residues (a type of protein glycosylation) (Bennett 1999).The

22

expression of this gene in the recurrent tumor is shown to increase. Higher than
normal levels of this gene in the brain could lead to increased glycosylation and
mutations in the cell cycle, thus, promoting abnormal cell proliferation.
SNCAIP is a synuclein interacting protein (Chung 2001). The validation
of this gene was chosen due to significant change of SNCA gene in the
microarray analysis. We were not able to validate the SNCA expression change
and therefore cannot make any conclusions about the SNCAIP expression change.
TPPP is known to promote aggregation of SNCA gene (Lindersson 2005).
Even though expression of this gene is significantly increased in the recurrent
tumor compared to the primary tumor, we cannot draw any conclusions about the
role of this gene in tumor proliferation since the SNCA gene validation was not
statistically significant. Nevertheless, the SNCA gene expression change from
microarray analysis and real time PCR did show a trend in the same direction.
SNCA has been known to play a role in neurodegenerative disorders; but more
research needs to be conducted to analyze its correlation with TPPP gene and
their role in proliferation of brain tumors.
Even though we were not able to validate the expressional change for
ANTXR1 gene, it is worth mentioning that latest research has shown some
correlation between ANTXR1 gene and other types of cancers. ANTXR1 has
been known to be involved in vasculogenesis (Nanda 2004). Vasculogenesis
involves the recruitment of blood supply for the tumor by forming new blood
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vessels. If the blood supply growth can be shut down, then the tumor can be
eliminated. This could be useful for future therapeutic interventions.
This study shows that Microarray analysis and real time PCR can be used
together to understand the gene expression change in GBMs. The findings can be
used to improve upon and/or invent new treatment options for GBM patients
which could, if not cure, increase the life expectancy of GBM patients.

Table 4: 18 gene functions with references that evaluate their relevance to cancer proliferation. The highlighted genes
24
were validated by qPCR analysis. Red indicates a decrease in expression change and green indicates an increase in
expression change in the recurrent GBM versus primary GBM

Gene

Function

Reference

ANTXR1

vasculogenesis

Nanda 2004

CCND2

cell cycle regulator

Lossos 2004

CLDN2

Tight junction

Thakur 2007

CSPG 3

regulation of extracellular matrix

Zhang 2003

CSPG4

regulation of extracellular matrix

Gladson 1999

CSPG5

regulation of extracellular matrix

Gladson 1999

EDIL3

angiogenesis

Aoka 2002

EGFR

cell signaling molecule

Wang 2004

ENPP2

adherence, motility

Kishi 2006

GALNT6

galactosaminotranserase

Bennett 1999

NPTX2

neuronal development

Carlson 2007

PTPRZ1

cell signaling

Lu 2005

SNCA

neurodegenerative disorders

Beyer 2008

SNCAIP

SNCA interacting protein

Chung 2001

ST18

transcriptional regulation

Steinbach 2006

STK17A

tumor suppressor

Wittig 2002

SYN2

synaptogenesis

Lee 2005

TPPP

promotes aggregation of SNCA

Lindersson 2005
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Summary:
Molecular Analysis of the Genetic Heterogeneity
Between Primary and Recurrent Glioblastoma
Glioblastoma multiforme (GBM) is one of the deadliest forms of brain
cancer, and affects more than 18,000 new cases each year in the United States
alone. Gliomas are defined as “a hetereogenous collection of neoplasms unified
by the fact that they arise from glial tissues,” (Grossman and Loftus, 1999). Glial
cells are non neuronal cells in the brain that are responsible for maintenance of
homeostasis, destruction of pathogens, removal of dead neurons, and provision of
insulation and oxygen for other neurons. There are two types of GBMs: Primary
and Recurrent. Primary GBMs are when the tumor remains at the site of origin.
On the other hand, in recurrent GBMs, the tumor has spread out to other parts of
the brain from the site of origin. Presentation of the tumor and patient profile is
very different for GBMs compared to any other type of tumor. Presentation of the
tumor in adults shows with severe, unbearable headaches due to the edema and
pushing of the tumor against the cranial chamber, seizures, bleeding,
decomposition, reduction of the brain’s ability to handle stressful situations or
stress in general, weak focal vision (Loftus and Grossman, 1999).
The current standard of treatment for GBM includes surgical removal of
the tumor, along with radiation and chemotherapy. Despite these treatments,
recurrence of GBM is extremely common, and once it recurs, the life expectancy
is measured in weeks or months. The treatment plan for recurrent tumor is the
same as the primary tumor depending on the health status of the patient. GBMs
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are more common in older age individuals; therefore, the patient’s health status is
usually not strong enough to handle another surgical operation with radiation and
chemotherapy treatments. There is a lot of debate over the palliative treatment
because if there is such a small time frame for survival, then why go through the
aggressive treatment once or even twice? A GBM case is presented differently
than any other form of cancer. Usually, a healthy patient is rushed into the
hospital due to severe headache or any other symptom, diagnosed with brain
tumor, taken to surgery usually at that visit, and then told that they only have
about one year left. The time bought from the surgery is very much appreciated
by the patients and it is also helpful for research purposes.
One of the reasons for the deadly nature of the recurrent GBM is thought
to be selection for therapy-resistant tumor cells. Research indicates that there are
certain genetic markers that differ from one grade to next grade of GBM. Certain
genes end up being over or under expressed as needed for the cancerous cells to
proliferate and spread throughout the brain (Ohgaki and Kleihues, 2005). In this
project, we specifically looked at cancer related gene expression changes that
showed consistent change in the microarray analysis in the recurrent vs. primary
tumors of DNA tissue from seven patients with both primary and recurrent GBMs
at Upstate Medical University. A total of 18 candidate genes (many with known
roles in cancer proliferation) were selected for the study from the microarray
results for validation: ANTXR1, CCND2, CLDN2, CSPG3, CSPG4, CSPG5,
EDIL3, EGFR, ENPP2, GALNT6, NPTX2, PTPRZ1, SNCA, SNCAIP, ST18,
STK17A, SYN2, and TPPP.
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Whole-genome DNA microarrays were used to identify genes changed in
mRNA expression in seven recurrent GBM samples compared to seven primary
GBM samples from the same subjects. Microarray GeneChip analysis uses
probes and targets for different applications such as mutations and differences in
expression on a chromosomal level. Screening shows markers that are
consistently changing, either increasing or decreasing. The assay mathematically
averages out the noise and finds strong, consistent change. A downside of this
method is that gene expression varies from person to person even in normal
individuals. Therefore, the findings of the Microarray analysis need to be
validated to make sure that the expressional changes are due to the cancer and not
just because normal biological genetic variation. As a result, Real-time
quantitative RT-PCR was used in an attempt to validate changes seen by
microarray for 18 genes of interest chosen from the microarray screen. Real Time
qPCR provides highly sensitive quantitative gene transcription measurements by
amplifying and quantifying DNA simultaneously. Once the reactions were run,
we asked two pertinent questions: a) Are there any common genes implicated
from the approach? and b) Are these genes implicated in cancer?
The microarray experiments identified several dozen mRNA transcripts
with evidence of significant differences in expression. From these genes, we
chose 18 for PCR validation. The results of this paper focus on the microarray
expression analysis and their validation using real time qPCR. On the microarray
screen, some of the genes are repeated because there was more than one probe for
that particular gene. T-test results show that most of the genes with expressional
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differences are statistically significant. The values that are not are the genes with
more than one probe. Majority of the probes for that specific gene are still
statistically significant. Expressional changes were averaged according to primary
minus recurrent tumors from each of the seven patients on a log 2 scale. A
negative value in the average log 2 column indicated a decrease in expression
while a positive value indicates an increase in gene expression. Overall, the PCR
experiments validated the microarray findings quite well. There was a very high
correlation for the magnitude of expression changes seen for the 18 genes
(Pearson’s R = 0.852, P < 0.001). Individually, 13 of the 18 genes showed
statistically significant changes by PCR in the recurrent versus primary tumor
pairs. Of the 5 genes that did not validate at the P<0.05 level, 4 showed trends in
the direction predicted by the microarray, while 1 gene did not.
The overall high correlation between the microarray expression analysis
and the qPCR validation results indicates that Real time PCR has proven useful
for validating changes in recurrent GBMs that could have important clinical
applications. Of the round 2 gene validation, 7 out of 12 genes were statistically
significant for expression change. The biology of these seven genes can be related
to tumor functions.
CCND2 is a cell cycle regulator (Lossos 2004). The average expression of
CCND2 is decreased in the recurrent tumor compared to the primary
tumor, thus, indicating that the high proliferation rate of the recurrent
tumor may be the result of improper function of cell cycle regulator.

32

CSPG3 (also known as NCAN), CSPG4, and CSPG5 belong to the same
family of genes. They are known to be responsible for the regulation of the
extracellular matrix (Gladson 1999 & Zhang 2003). Real time validation
showed that the average expressions in all three genes are decreased in the
recurrent tumor. This shows that since the matrix is not regulated, the
tumor cells can easily spread to the neighboring cells because there is not
traffic in the extracellular matrix to slow down the proliferation of the
tumor cells.
GALNT6 is known to be expressed in low levels in the brain. It is
associated with fibronectin glycosylation kinetics. Furthermore, members
of this family are responsible for the transfer of N-acetylgalactoamine to
serine and threonine residues ( a type of protein glycosylation) (Bennett
1999).The expression of this gene in the recurrent tumor is shown to
increase. Higher than normal levels of this gene in the brain could lead to
increased glycosylation and mutations in the cell cycle, thus, promoting
abnormal cell proliferation.
SNCAIP is a synuclein interacting protein (Chung 2001). The validation
of this gene was chosen due to significant change of SNCA gene in the
microarray analysis. We were not able to validate the SNCA expression
change and therefore cannot make any conclusions about the SNCAIP
expression change.
TPPP is known to promote aggregation of SNCA gene (Lindersson 2005).
Even though expression of this gene is significantly increased in the
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recurrent tumor compared to the primary tumor, we cannot draw any
conclusions about the role of this gene in tumor proliferation since the
SNCA gene validation was not statistically significant. Nevertheless, the
SNCA gene expression change from microarray analysis and real time
PCR did show a trend in the same direction. SNCA has been known to
play a role in neurodegenerative disorders; but more research needs to be
conducted to analyze its correlation with TPPP gene and their role in
proliferation of brain tumors.
Even though we were not able to validate the expressional change for
ANTXR1 gene, it is worth mentioning that latest research has shown some
correlation between ANTXR1 gene and other types of cancers. ANTXR1
has been known to be involved in vasculogenesis (Nanda 2004).
Vasculogenesis involves the recruitment of blood supply for the tumor by
forming new blood vessels. If the blood supply growth can be shut down,
then the tumor can be eliminated. This could be useful for future
therapeutic interventions.
This study shows that Microarray analysis and real time PCR can be used
together to understand the gene expression change in GBMs. The findings can be
used to improve upon and/or invent new treatment options for GBM patients
which could, if not cure, increase the life expectancy of GBM patients.

